This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| A. | Classification codes | ICD-10 M88.9 | Special Copayment Reduction V213 |
| B. | Synonyms | — |
| C. | Adult onset | Very high (essentially an adult-only disease) — Paget disease in which the involved site is not clearly recorded; generally begins after age 50. |
| 1. | History | Chronic bone remodeling disorder described by James Paget (1877); changes in naming and classification. |
| 2. | Causes | Multiple causes, including SQSTM1 mutations and environmental factors such as paramyxovirus. |
| 3. | Genetics | Associated with multiple genes including SQSTM1 (8q24); autosomal dominant or sporadic. |
| 4. | General epidemiology | Prevalence 1–3% in older adults of Western European descent aged 50 or older; rare in Asia. |
| 5. | Pathophysiology | Osteoclast overactivity → disorganized bone remodeling → formation of mosaic lamellar bone. |
| 6. | Symptoms | Pain, deformity, fractures, nerve compression; when the site is unknown, systemic symptoms are in the foreground. |
| 7. | Signs | Elevated serum ALP; increased lesional uptake on bone scan. |
| 8. | Screening | ALP measurement; whole-body bone scan. |
| 9. | Diagnosis | Serum ALP + imaging (X-ray, CT, MRI) + tissue biopsy. |
| 10. | Treatment | Bisphosphonates (single IV infusion of zoledronic acid); pain control. |
| 11. | Prognosis | Favorable with appropriate treatment; risk of sarcomatous transformation ~1%. |
| 12. | Prevention | No established prevention; complications minimized by early detection and treatment. |
| 13. | References | List of key references and guidelines |
Paget disease of bone (PDB) was first systematically described in 1877 by the English surgeon Sir James Paget (1814–1899). Paget named the disease "osteitis deformans" at the time and described bone enlargement and deformity due to a chronic inflammatory process as its key features. At first it was merely a rare clinical description, but in the 20th century, as X-ray imaging became widespread, the diagnosis rate rose sharply. In the 1960s–1970s, serum alkaline phosphatase (ALP) was established as an indicator of disease activity, and bone scintigraphy began to be used to assess the extent of involvement. In the ICD classification system, Paget disease was subdivided by site into skull (M88.0), other bones (M88.8), and unspecified (M88.9), with M88.9 used when the involved site is not specified in the medical record or imaging. In the 1990s, bisphosphonates became the standard treatment, and in 2005 a single-infusion regimen of zoledronic acid demonstrated superior remission rates compared with oral risedronate in clinical trials. Since the 2000s, molecular genetic research has shown that SQSTM1 gene mutations are a major cause of familial PDB. Given the epidemiology of Paget disease, with high prevalence in Western European and British emigrant lineages and rarity in people of Asian descent, research on geographic and genetic susceptibility continues.
In clinical practice, the M88.9 code is used when lesions are multiple or it is difficult to specify a single site, or as a provisional code at the initial visit before further imaging is read. Even when the unspecified code is used alone in this way, the principles of clinical management are the same as for M88.0 and M88.8, and it is recommended to revise and supplement the code once the site is confirmed later.
The cause of Paget disease is understood as multifactorial, with genetic predisposition and environmental factors acting in combination. The best-characterized genetic cause is mutation of the SQSTM1 (sequestosome-1) gene located on the long arm of chromosome 8, identified in about 30–40% of patients with familial PDB. The SQSTM1 product, p62 protein, is a regulator of the NF-κB signaling pathway, and when mutated, osteoclast precursor cells become hypersensitive to RANKL, forming clones of overactive osteoclasts. As environmental factors, the hypothesis of persistent infection with measles virus and paramyxovirus was strongly proposed in the past, but recent molecular epidemiological studies have not clearly demonstrated a direct causal relationship, and the debate continues. Other proposed environmental factors include exposure to heavy metals such as lead and cadmium, a history of animal contact (canine distemper virus), and geographic clustering.
Sporadic (nonfamilial) PDB occurs even without genetic mutations, and in such cases epigenetic changes or unknown environmental exposures are presumed to be involved. Variants in genes such as ZNF687, CSF1, RIN3, and TM7SF4 have also been reported in genome-wide association studies (GWAS) to be associated with increased PDB risk.
The SQSTM1 gene (8q24.12) is central to the genetics of Paget disease, and more than 30 pathogenic mutations have been reported to date. The most common variant is p.Pro392Leu (P392L), which impairs ubiquitin binding of the UBA domain and induces NF-κB overactivity. SQSTM1 mutation carriers have low penetrance, so not all family members develop the disease, and age, sex, and environmental factors play important roles in phenotypic expression. Familial PDB shows an autosomal dominant pattern but with incomplete penetrance.
GWAS studies have identified multiple susceptibility loci, including TNFRSF11A (RANK), TNFRSF11B (OPG), CSF1, RIN3, OPTN, TM7SF4, and ZNF687. Most of these genes are involved in osteoclast differentiation and activation or in the autophagy pathway, reflecting the complex genetic architecture of PDB pathophysiology. Early-onset PDB in childhood and adolescence has also been reported in association with gain-of-function mutations of the RANK gene in addition to SQSTM1 variants.
Paget disease is a relatively common bone disease with a prevalence of up to 1–3% in people aged 50 or older of Western European descent, especially of British, Irish, Italian, and French lineage. In the United Kingdom, before the 1990s it was diagnosed by X-ray or ALP abnormalities in more than 5% of men aged 65 or older, but over the last 20–30 years both prevalence and severity have shown a declining trend. Men are affected about 1.4 times more often than women. It is very rare in Asia (Korea, Japan, China), Africa, and Scandinavia, where it qualifies as a rare disease.
Patients recorded under the M88.9 (unspecified) code are a subset of all PDB, arising when site confirmation is incomplete at the initial visit or when medical records are incomplete. In Korean health insurance claims data, the M88 series is recorded very rarely, and most cases are diagnosed through incidental ALP elevation or radiographic findings. When there is a family history, the risk in first-degree relatives is about 7–10 times higher than in the general population.
The pathogenesis of Paget disease begins with quantitative and functional abnormalities of osteoclasts. In normal bone remodeling, the coupled process in which osteoclasts perform bone resorption and osteoblasts fill in new bone matrix is tightly regulated. In PDB, owing to SQSTM1 mutations or abnormal RANK signaling, osteoclast precursor cells respond hypersensitively even to very low concentrations of RANKL, and giant multinucleated osteoclasts proliferate excessively at lesion sites. These hyperproliferating osteoclasts contain tens of times the normal number of nuclei and markedly increase the rate of bone resorption.
Osteoblasts increase compensatorily in response to excessive bone resorption, but the newly formed bone is filled with woven bone in a disorganized mosaic pattern instead of normal lamellar bone. This abnormal bone has low mechanical strength and increased vascularity, making it vulnerable to deformity, pathological fracture, and pain. Bone blood flow increases greatly at the local level and can rarely cause high-output cardiac failure. In the long term, it rarely undergoes malignant transformation to Paget sarcoma, which has a very poor prognosis.
Paget disease is often asymptomatic at diagnosis and is discovered through incidental serum ALP elevation or imaging findings. When symptoms are present, the most common is deep aching pain, characteristically persisting even at night. The pain arises from vasodilation and nerve irritation in the bone itself or may be aggravated by secondary degenerative arthritis. When long bones (femur, tibia) are involved, progressive bowing (bow-legged deformity) develops, causing gait impairment.
With skull involvement, skull enlargement, headache, hearing loss (narrowing of the ear canal or cochlear involvement), and cranial nerve compression may occur. With spinal involvement, low back pain and neuropathy due to spinal cord compression may be present. Rarely, pathological fracture is the first symptom. When classified as M88.9, site-specific symptoms are often not prominent, or only systemic ALP abnormalities are present.
Clinical signs that may be observed include increased skin temperature over the involved site (increased local blood flow), changes in body shape due to bone enlargement (skull enlargement, bowing of long bones), and a vascular bruit over the skull on auscultation. Serum ALP is the most sensitive and clinically useful indicator reflecting disease activity and extent of involvement, and isolated ALP elevation is often the first clue to PDB. Bone-specific ALP or serum/urine collagen cross-links (NTX, CTX) are also used as bone resorption markers.
On whole-body bone scan (99mTc-MDP), a markedly increased uptake of radiotracer at lesion sites is characteristic. On X-ray, specific findings such as bone expansion, cortical thickening, cotton-wool appearance (skull), and a flame-shaped lytic front (long bones) are observed. Even when the unspecified code is used, the diagnosis is made on the basis of these laboratory and imaging findings.
The most efficient and cost-effective method of screening for PDB is measurement of serum total ALP. Unexplained ALP elevation (normal liver function, especially normal γ-GTP) suggests a bone origin and prompts further evaluation to differentiate metabolic bone diseases including PDB. There are guidelines recommending ALP testing every 5 years after age 40 for first-degree relatives of SQSTM1 mutation carriers.
A whole-body bone scan is excellent for comprehensively assessing the sites and extent of involvement, and when PDB is suspected, whole-body imaging should always be performed to check for multiple sites. For screening purposes, simple ALP measurement comes first, and if abnormal, one proceeds in the order bone scan → site-specific X-ray, CT, MRI. When abnormal uptake is confirmed on bone scan and plain X-ray shows characteristic findings, a clinical diagnosis is possible without tissue biopsy.
The diagnosis of PDB is made by integrating characteristic clinical, biochemical, and imaging findings. The key diagnostic criteria are (1) elevated ALP (bone-specific or total ALP), (2) characteristically increased uptake on whole-body bone scan, and (3) bone expansion, cortical thickening, and mosaic findings on X-ray of the lesion site. A clinical diagnosis is possible when two or more of the three are consistent, and core biopsy is needed for atypical findings or suspected malignant transformation.
The M88.9 (unspecified) code applies when a single site is not clearly determined, when there are multiple sites but further classification is incomplete, or when it is assigned as a provisional code at the initial visit in the absence of detailed imaging. After the diagnosis is confirmed, accurate coding is to update it to M88.0 or M88.8 according to the involved site. Differential diagnoses include bone metastases, fibrous dysplasia, malignant bone tumors, primary hyperparathyroidism, and renal osteodystrophy.
The first-line treatment of Paget disease is bisphosphonates, and among them a single IV infusion of zoledronic acid 5 mg is currently recommended as the most effective treatment. In the PRISM study (Reid et al., 2005), zoledronic acid showed superior results compared with oral risedronate in both the ALP normalization rate and the duration of treatment response. Oral bisphosphonates (risedronate 30 mg/day for 2 months, alendronate 40 mg/day for 6 months) are also used as alternatives. Pain is controlled with NSAIDs and acetaminophen, and when degenerative arthritis develops, physical therapy, orthoses, and joint replacement are considered.
The goals of treatment are to lower ALP to the normal range and relieve symptoms. Long-term follow-up is needed even after ALP normalizes, and retreatment is considered upon reactivation. Surgical indications include pathological fracture, total joint replacement, cranial decompression, and spinal cord decompression. When malignant transformation to Paget sarcoma occurs, chemotherapy, radiotherapy, and wide resection are performed according to osteosarcoma protocols.
In most patients with Paget disease, appropriate bisphosphonate treatment improves symptoms and normalizes ALP, and the long-term prognosis is favorable. Remission is often maintained for several years after treatment, but in some reactivation occurs and retreatment is needed. Mortality from Paget disease itself does not differ from the general population, but the prognosis worsens markedly when complications (pathological fracture, spinal cord compression, heart failure, Paget sarcoma) occur.
Paget sarcoma is a rare malignant complication occurring in about 0.5–1% of all PDB patients, with a 5-year survival rate of only 5–10%. Hearing loss, gait impairment due to nerve compression, and secondary arthritis are major factors affecting functional prognosis. Regular follow-up (ALP, bone scan) and prompt evaluation of new pain or functional decline are key to early detection of complications.
To date, no primary prevention for Paget disease has been established. When there is a genetic predisposition (SQSTM1 mutation carriers or a family history of PDB), pursuing early detection through regular ALP testing after age 40 is the core of secondary prevention. In groups at risk of familial PDB, a bone scan is performed when ALP is abnormal even at the presymptomatic stage, securing the opportunity for early treatment. Regarding prophylactic use of bisphosphonates (in asymptomatic SQSTM1 variant carriers), results from randomized controlled studies are still lacking, and current guidelines do not recommend it.
In terms of preventing complications (tertiary prevention), adequate intake of calcium (1000–1200 mg/day) and vitamin D (800–1000 IU/day) to maintain bone health, fall prevention education, and regular physical activity are important. Fracture prevention programs for older patients at high risk of falls, hearing tests, ophthalmic follow-up, and neurology consultation are recommended as part of complication prevention.